{"id":"arbidol-umifenovir","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL1214598","moleculeType":"Small molecule","molecularWeight":"477.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Umifenovir is a broad-spectrum antiviral that targets the fusion process of enveloped viruses, including influenza and other respiratory viruses. It binds to viral hemagglutinin and prevents the conformational changes necessary for the virus to fuse with the host cell membrane, thereby blocking viral entry and infection.","oneSentence":"Arbidol inhibits viral fusion by blocking the interaction between viral envelope proteins and host cell membranes, preventing viral entry into cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:35.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza A and B prophylaxis and treatment"},{"name":"Acute respiratory viral infections"},{"name":"COVID-19 (in some markets, though efficacy remains debated)"}]},"trialDetails":[{"nctId":"NCT03851991","phase":"PHASE4","title":"The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.","status":"COMPLETED","sponsor":"Shengjing Hospital","startDate":"2019-08-30","conditions":"COPD Patients","enrollment":351},{"nctId":"NCT03787459","phase":"PHASE3","title":"Severe Influenza Trial of ARbidol","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2019-01-18","conditions":"Influenza","enrollment":200},{"nctId":"NCT06462417","phase":"NA","title":"Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis","status":"RECRUITING","sponsor":"Zheng Liu","startDate":"2024-07-11","conditions":"Allergic Rhinitis","enrollment":15},{"nctId":"NCT05783206","phase":"PHASE2, PHASE3","title":"Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19","status":"COMPLETED","sponsor":"National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia","startDate":"2022-02-10","conditions":"COVID-19","enrollment":984},{"nctId":"NCT04260594","phase":"PHASE4","title":"Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","status":"COMPLETED","sponsor":"Jieming QU","startDate":"2020-02-08","conditions":"2019-nCoV","enrollment":236},{"nctId":"NCT04476719","phase":"PHASE1","title":"The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions","status":"UNKNOWN","sponsor":"Atabay Kimya Sanayi Ticaret A.S.","startDate":"2020-07-09","conditions":"Bioequivalence","enrollment":18},{"nctId":"NCT04252885","phase":"PHASE4","title":"The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection","status":"COMPLETED","sponsor":"Guangzhou 8th People's Hospital","startDate":"2020-01-28","conditions":"Coronavirus Infections","enrollment":86},{"nctId":"NCT04350684","phase":"PHASE4","title":"Umifenovir in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04286503","phase":"PHASE4","title":"The Clinical Study of Carrimycin on Treatment Patients With COVID-19","status":"UNKNOWN","sponsor":"Beijing YouAn Hospital","startDate":"2020-02-23","conditions":"Novel Coronavirus Infectious Disease (COVID-19)","enrollment":520},{"nctId":"NCT01651663","phase":"PHASE4","title":"A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold","status":"UNKNOWN","sponsor":"Pharmstandard","startDate":"2011-09","conditions":"Influenza","enrollment":840}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"OFF LABEL USE"}],"_approvalHistory":[],"publicationCount":175,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Arbidol (Umifenovir)","genericName":"Arbidol (Umifenovir)","companyName":"Pharmstandard","companyId":"pharmstandard","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arbidol inhibits viral fusion by blocking the interaction between viral envelope proteins and host cell membranes, preventing viral entry into cells. Used for Influenza A and B prophylaxis and treatment, Acute respiratory viral infections, COVID-19 (in some markets, though efficacy remains debated).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}